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Cardiovascular disease linked to atherosclerosis is the leading cause of death worldwide. Atherosclerosis is mainly linked to
dysfunction in vascular endothelial cells and subendothelial accumulation of oxidized forms of LDL. In the present study, we
investigated the role of myeloperoxidase oxidized LDL (Mox-LDL) in endothelial cell dysfunction. We studied the effect of
proinflammatory Mox-LDL treatment on endothelial cell motility, a parameter essential for normal vascular processes such as
angiogenesis and blood vessel repair. This is particularly important in the context of an atheroma plaque, where vascular wall
integrity is affected and interference with its repair could contribute to progression of the disease. We investigated in vitro the
effect of Mox-LDL on endothelial cells angiogenic properties and we also studied the signalling pathways that could be affected
by analysing Mox-LDL effect on the expression of angiogenesis-related genes. We report that Mox-LDL inhibits endothelial cell
motility and tubulogenesis through an increase in miR-22 and heme oxygenase 1 expression. Our in vitro data indicate that Mox-
LDL interferes with parameters associated with angiogenesis. They suggest that high LDL levels in patients would impair their
endothelial cell capacity to cope with a damaged endothelium contributing negatively to the progression of the atheroma plaque.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of
death worldwide. According to the 2005 World Health
Organization report, CVD is responsible for 30% of all
deaths globally. CVD commonly stems from vascular dys-
function, which is mainly linked to atherosclerosis. The
accumulation of oxidized forms of LDL (ox-LDL) in
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2014, Article ID 134635, 14 pages
http://dx.doi.org/10.1155/2014/134635
2 Mediators of Inflammation
the intima of blood vessels is widely accepted to play a major
role in the development of atheroma plaques. LDL particles
are oxidized in situ; small amounts can also be found in the
circulation and are therefore in contact with the endothelial
cells (ECs) [1–3]. Wherever these particles are modified,
myeloperoxidase (MPO) is nowadays the best candidate as an
in vivo actor in LDL modification whereas other candidates
(such as lipoxygenases, NADPH oxidases, and endogenous
copper) were previously considered [4]. MPO is an enzyme
secreted by activated neutrophils; it catalyses the production
of hypochlorous acid from hydrogen peroxide and chloride.
The generated HOCl is responsible for the modification of
LDLs into chlorinated LDLs (HOCl-LDLs) [5].
Furthermore, serum MPO levels are markers of adverse
prognosis in patients with acute coronary syndromes [6].
Mox-LDLs are endowed with proinflammatory properties.
Mox-LDL indeed triggers IL-8 gene expression by endothelial
cells and monocytes and macrophages, respectively [4]. They
also interfere with EC function. The endothelial dysfunc-
tion involves expression of adhesion molecules recruiting
immune cells to the endothelium and allowing them to
penetrate into lesions [7]. Among the recruited cell types are
monocytes, which, once in the intima, will differentiate into
macrophages, engulf atherogenic oxidized lipoproteins, and
evolve into the so-called foam cells. Foam cell accumulation
contributes to the formation of an atheroma core which will
further evolve into a mass of necrotic cells, cholesterol, and
lipid debris [8]. This process is considered the hallmark of
early atherosclerosis. Endothelial dysfunction also impedes
EC motility and migration [9, 10]; EC motility is a funda-
mental aspect of angiogenesis, an essential process involved
in many physiological and pathological processes [11–13]. It
could also be critical in cases of endothelium desquamation
associated with the presence of circulating ECs correlated
to many pathologies such as vasculitis, lupus erythematosus,
sickle cell anemia, thalassemia, septic shock, infections (rick-
ettsiae, CMV), or cancer [14]. As far as atherosclerosis is con-
cerned, circulating ECs are associated with plaque ruptures,
stroke, or myocardial infarctions [15]. Physical denudation
of the ECs bed has been described at atheroma plaque
locations and a failure to locally regenerate the endothelium
is suspected to be deleterious to the endothelium function
[16]. Also post-AMI (acute myocardial infarction) vascular
reconstruction surgery and stenting procedures have been
doomed to failure due to restenosis which is thought to
be linked to the inability of the endothelium to regenerate
and heal the denuded regions [13]. Another phenomenon
involving EC growth and associated with CVD is stent
reendothelialization. Finally, most of the procedures involved
in stenosis or aneurysm treatments involve catheterization
associated with vascular wall denudation [17].
The question arises whether oxidized LDL, on top of
being instrumental in atheromaplaque formation, would also
interfere with the ability to heal the associated endothelium
whether this damage is subsequent to atherosclerosis or not.
In order to address this question, we investigated the possible
effect of physiologically modified LDL on EC motility and
survival as well as gene expression and signal transduction.
We report that pathological concentrations ofMPO-modified
LDLs inhibit EC mobility and angiogenic properties and that
this defect relies on miR-22 and heme oxygenase 1 (HO-1)
increase.
2. Material and Methods
2.1. Cell Culture, Transfection, and Gene Knockdown and
Overexpression. Clonetics HUVEC Cells (Lonza) were cul-
tured in complete Clonetics EBM Endothelial Growth
Medium (Lonza; Cat. number CC-312) at 37∘C, 5% (v/v)
CO
2
according to the provider’s recommendations. Cell
transfections were carried out using Gene Trans II according
to the manufacturer’s instructions (MobiTec; Cat. number
0102B). For miR-22 selective knockdown and inhibition, we
used miRCURY LNA microRNA inhibitor [hsa-miR-22∗]
supplied by Exiqon (product number 411669-00) (sequence:
AAGCTTGCCACTGAAGAAC). For quality assessment of
the knockdown experiment, we used a miRCURY LNA
microRNA inhibitor negative control (sequence: GTGTAA-
CACGTCTATACGCCCA). For HO-1 overexpression, we
used the TrueClone pCMV6AC-HMOX1(NM 002133.1) vec-
tor supplied by OriGene (SKU SC320297).
2.2. Measuring Cell Behavior Using the xCELLigence System.
The detailed protocol was thoroughly described previously
[18]. Briefly, 50 𝜇L of EBM at room temperature was added
into eachwell of E-plate 16.TheE-plate 16was then connected
to the system and checked in the cell culture incubator for
proper electrical contacts and the background impedance
was measured during 24 s. HUVECs were resuspended in
EBM and adjusted to 103 cells/𝜇L. 100 𝜇L of the cell sus-
pension was added to the wells on E-plate 16 and the plate
was then placed back to the incubator. Approximately 24
hours after seeding, the cells were exposed to 100 𝜇L of
control medium or medium containing either native LDL
or Mox-LDL at a final concentration of 100𝜇g/mL. Controls
received EBM medium only. Cell behavior was monitored
every 20min by the xCELLigence system for a period of 48
hours via the incorporated sensor electrode arrays of the
E-Plate 16. The electrical impedance was measured by the
RTCA-integrated software of the xCELLigence system as a
dimensionless parameter termed Cell Index (CI).
2.3. Tubulogenesis Assay. TheMatrigel tube formation assay,
or tubulogenesis assay, was performed to assess the ability
of HUVECs to form endothelial cell vascular structures
(or tubules) involved in vessel formation (angiogenesis). As
previously described [19], individual wells were coated with
100 𝜇L of Matrigel Basement Membrane Matrix (BD Bio-
sciences; Cat. number 356234) in a 24-well plate and allowed
to polymerize at 37∘C for 2 hours. After polymerization,
250 𝜇L of complete EBM was added to each well and the
plate was incubated for an additional hour at 37∘C. 5 × 104
HUVECs (which were either treated or not with native LDL
andMox-LDL for 24 hours) were then resuspended in 500𝜇L
of complete EBM (Lonza; Cat. number CC-312) (± native
LDL or Mox-LDL at a final concentration of 100 𝜇g/mL) and
were added to each well in duplicate. After an overnight
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incubation, cells were inspected for tubule formation and
pictures were taken from three fields of views using inversed
light microscopy with the 4x objective. The tubule networks
lengths were measured using the Image J program, averaged
between the fields of views and duplicates, and expressed
as a percentage of control untreated cells. Experiments were
reproduced 3 times independently.
2.4. Tubulogenesis in Real-Time. The procedure was con-
ducted as described above with the exception that the
cells were incubated in a 37∘C conditioned chamber of an
AxioVision-Carl Zeiss microscope and the microscope was
set to automatically take pictures at 10min intervals over a 9-
hour period. The culture medium was buffered with HEPES
at a 15mM final concentration to compensate for the CO
2
unavailability in our setup.
2.5. In Vitro Wound-Healing Assay. HUVEC migration was
monitored using the wound-healing assay as previously
described [20]. Briefly, 7 × 104 cells/well/mL were seeded
in 24-well plates in EBM medium (± native LDL or Mox-
LDL at a final concentration of 100𝜇g/mL). After a 24-hour
incubation allowing the cells to attach and form a confluent
monolayer, the cells were scraped with a conserved width
using a yellow tip. After scraping, cells were washed with
PBS and were incubated in EBM with or without native
LDL/Mox-LDL at final concentrations of 100 𝜇g/mL. Scratch
width was photographed at times 0 and 8 hours from three
fields of views using the 20x objective with a microscopic
camera system coupled to an inverted light microscope. The
experiments were performed in duplicate. Using the Image J
program, the wound sizes were measured by calculating the
distance between the wound edges which remained cell-free
at 𝑡 = 8 h, averaged between the fields of views and duplicates
and expressed as a percentage of the initial wound width at
𝑡 = 0 h.
2.6. Cell Migration Assay. As previously described [21], cell
migration assays were carried out using modified Boyden
chambers consisting of Transwell membrane filter inserts
(Greiner Bio-one; Cat. number 662631) in 24-well tissue
culture plates. The translucent Transwell membranes were
6.5mm in diameter with a pore size of 8𝜇m. The upper
surfaces of the Transwell membranes were coated with
fibronectin and the Transwells were initially incubated for
2 hours at 37∘C and then overnight at 4∘C. The second day,
the inserts were rinsed once with EBM medium and then
placed into 24-well tissue culture plates containing 600 𝜇L
of EBM medium/well. HUVECs (1.5 × 105 cells treated or
not treated with either native LDL or Mox-LDL for 24
hours) in 100 𝜇L of EBM medium (± native LDL or Mox-
LDL at a final concentration of 100𝜇g/mL) were seeded into
the upper side of each Transwell chamber and the native
LDL or Mox-LDL preparations were added simultaneously
(at a final concentration of 100𝜇g/mL) with a chemotactic
agent (VEGF at 0.4 𝜇g/mL) to the lower compartment of
the Boyden chambers. After incubation for 8 hr at 37∘C,
the cells remaining on the upper membrane surface were
removed by wiping with a cotton swab, and filters were
fixed with 4% paraformaldehyde and stained with crystal
violet. The number of cells per membrane lower surface was
counted under a lightmicroscope using the 20x objective.The
experiments were performed in duplicate and the numbers
of invaded cells were averaged between the duplicates and
expressed as a fold/control untreated cells.
2.7. Study of Cell Death and Cell Proliferation by Flow
Cytometry. Confluent HUVECs were either treated or not
treated with native LDL or Mox-LDL at a final concentration
of 100𝜇g/mL for 24 hours. Cell death was detected using
the LIVE/DEAD Fixable Red Dead Cell Stain Kit (Molecu-
lar Probes; Cat. number L-23102) following manufacturer’s
instructions. HUVECs were harvested and stained with the
near-IR Dead Cell Stain which is excited at a 633/635 nm
wavelengths. For proliferation analysis, BD Pharmingen Ki67
kit was used and the assay was also performed according
to manufacturer’s instructions. In brief, after staining with
the Red Dead Cell Stain, cells were fixed, permeabilized, and
then stained with FITC-Ki67 (BD Pharmingen, San Diego,
CA, USA; Cat. number 612472) for 20 min at 4∘C. Cells
were then analyzed using BD FACSCanto II flow cytometry,
and data were analyzed using FlowJO (Tree Star, inc.©). The
experimentswere performed in duplicate and the percentages
of proliferating and dead cells were averaged between the
duplicates.
2.8. PI/Annexin V Staining and Flow Cytometry Analysis to
Study Apoptosis. HUVECs were either treated or not treated
with native LDL or Mox-LDL at a final concentration of
100 𝜇g/mL for 24 hours. Apoptosis was detected using BD
Pharmingen FITC Annexin V Detection Kit 1. The assay was
performed according to manufacturer’s instructions. In brief,
HUVECs were washed twice with cold PBS and resuspended
in Binding Buffer at a concentration of 106 cells/mL. FITC
Annexin V and PI were added and cells were vortexed
gently and incubated in the dark at room temperature for
15min. Flow cytometry analysis was performed within 1
hour using BD FACSCanto II flow cytometry, and data were
analyzed using FlowJO (Tree Star, inc.©). The experiments
were performed in duplicate and the percentages of annexin
V positive and PI positive cells were averaged between the
duplicates.
2.9. Western Blot Analysis of Phospho-FAK. HUVECs were
either treated with mock medium or Mox-LDL at a final
concentration of 100𝜇g/mL for 24 hours. Cells were then
solubilized in Laemmli Sample Buffer. Total cellular protein
extracts were separated by SDS-PAGE, electrotransferred to
PDVF membranes, analyzed with anti-p-FAK (Tyr 576)-R
antibody (200𝜇g/mL; 1 : 200; Santa Cruz Biotechnology), and
detected with Western Lightning-ECL (PerkinElmer Inc).
2.10. Immunofluorescence. HUVECs were either treated with
mock medium or Mox-LDL at a final concentration of
100 𝜇g/mL for 24 hours. Cells were then seeded onto
fibronectin-coated coverslips. The next day, cells were fixed
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in 4% paraformaldehyde, permeabilized in 0.1% Triton X-
100, blocked in BSA, and incubated overnight with the appro-
priate primary antibody. Cells were then further incubated
with the corresponding secondary antibodies for 1 h. After
washing, cells were mounted with Fluoro-Gel (Laborimpex)
and processed for immunofluorescence using a Nikon fluo-
rescence confocal microscope (Nikon A1R).
2.11. HUVECs MicroRNA Profiling and Data Analysis.
HUVECs were either treated or not treated with native LDL
or Mox-LDL at a final concentration of 100𝜇g/mL for 24
hours. Total RNA was extracted from cells using TRIzol
total RNA isolation reagent (Roche Applied Science). To
profile microRNA expression in the treated and nontreated
HUVECs, a two-step procedure was then performed. First,
for cDNA synthesis from the miRNAs, 1000 ng of the
extracted total RNA was subjected to reverse transcription
(RT) using the TaqMan microRNA reverse transcription kit
(Applied Biosystems) and Megaplex RT primers (Human
Pool A, Applied Biosystems) following the manufacturer’s
instructions, allowing simultaneous reverse transcription
of 380 mature human miRNAs. RT was performed on a
Mastercycler Epgradient thermocycler (VWR). After the RT
step, cDNA was diluted in RNase-free water, combined with
TaqMan gene expression master mix, and loaded into the
TaqMan Human MicroRNA Array A (Applied Biosystems).
This microRNA array is a 384-well real-time PCR-based
microfluidic card with embedded TaqMan primers and
probes in each well corresponding to 380 different mature
human miRNAs. Quantitative RT-PCR was performed on
an ABI PRISM 7900HT sequence detection system (Applied
Biosystems) according to the manufacturer’s instructions.
The relative expression levels of miRNAs were calculated
by the SDS 2.3 software (Applied Biosystems) using the
comparative ΔΔCt method and RNU48 as endogenous
control.
2.12. TaqMan miRNA Assay for Individual miRNAs. Cells
were either treated or not with native LDL or Mox-LDL
at a final concentration of 100𝜇g/mL for 24 hours and
total RNA was extracted from cells using TRIzol total RNA
isolation reagent (Roche Applied Science). According to the
manufacturer’s instructions, The TaqMan microRNA reverse
transcription kit (Applied Biosystems) was used to perform
gene-specific reverse transcription for each microrna using
10 ng of purified total RNA, 100mm dNTPs, 50 units of
MultiScribe reverse transcriptase, 20 units of RNase inhibitor,
and 50 nm gene-specific RT primer samples. Real-time PCRs
were carried out on an ABI Prism 7900HT sequence detec-
tion system (Applied Biosystems) using 5 𝜇L of the RT
product, 10 𝜇L of TaqMan 2x universal PCR master mix
(Applied Biosystems), 1𝜇L of TaqMan microRNA assay mix
(containing PCR primers and TaqMan probes) according to
the manufacturer’s instructions. All quantitative RT-PCRs
were performed in triplicate and the relative expression
levels of miRNAs were calculated by the SDS 2.3 soft-
ware (Applied Biosystems) using the comparative ΔΔCt
method.
2.13. Quantitative Real-Time PCR. Cells were either treated
or not with native LDL or Mox-LDL at a final concentration
of 100 𝜇g/mL for 24 hours. Total RNA was extracted from
cells usingTRIzol total RNA isolation reagent (RocheApplied
Science) and reverse-transcribed using Reverse Transcrip-
tase Core Kit (Eurogentec) according to the manufacturer’s
instructions. qRT-PCR was performed in 96-well plate for-
mat using SYBR Green-based detection on a Step-One-
Plus machine (Applied Biosystems) with each 20𝜇L reac-
tion containing ∼50 ng cDNA, 0.3 𝜇M sense and antisense
primers, andABsolute qPCR SYBRGreenROXMix (Thermo
Scientific). The plate was sealed and cycled under the fol-
lowing conditions: 95∘C for 15min, 40 cycles of 95∘C for
15 s, 60∘C for 30 s, and 72∘C for 30 s. Each reaction was
performed in triplicate andmRNA levels of RPL27 were used
for normalization. The relative expression levels of mRNAs
were calculated using the comparative ΔΔCt method. PCR
primers used for the quantification of HO-1 and RPL27 were
as follows:
HO-1 forward primer 5󸀠-AAGACTGCGTTCCTG-
CTCAAC-3󸀠;
HO-1 reverse primer 5󸀠-AAAGCCCTACAGCAA-
CTGTCG-3󸀠;
RPL27 forward primer 5󸀠-ATCGCCAAGAGATCA-
AAGATAA-3󸀠;
RPL27 reverse primer 5󸀠-TCTGAAGACATCCTT-
ATGACG-3󸀠.
2.14. QRT-PCR Based StellARray System to Study Angio-
genesis. Cells were either treated or not with native LDL
or Mox-LDL at a final concentration of 100𝜇g/mL for 24
hours. Total RNA was extracted from cells using TRIzol
total RNA isolation reagent (Roche Applied Science) and
reverse-transcribed using Reverse Transcriptase Core Kit
(Eurogentec) according to the manufacturer’s instructions.
For expression analysis of 94 preselected genes involved
in angiogenesis, Human Angiogenesis 96-well StellARray
qPCR array (Lonza Ltd., Switzerland) was used according to
manufacturer’s instruction with ABsolute qPCR SYBRGreen
ROX Mix (Thermo Scientific) on an ABI Prism 7900HT
sequence detection system (Applied Biosystems). Data were
analyzed with Global Pattern Recognition Data Analysis
Tool (Bar Harbor Biotechnology, Trenton, ME, USA) using
the internal array control housekeeping gene expression for
normalization.
2.15. MicroRNA Target Prediction. The microRNA:mRNA
target predictions were downloaded from public websites
TargetScan algorithm release 4.1 (http://www.targetscan.org)
and miRanda algorithm (http://www.microrna.org).
2.16. Recombinant MPO Preparation. Recombinant MPO
was prepared as described previously. Briefly, in order to
express MPO, a recombinant plasmid that codes for pre-
promyeloperoxidase was constructed and named pNIV2703.
This plasmid contains an MPO fragment coding for amino
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acid 11 in the putative signal sequence to amino acid 696.The
pNIV2703 expression vector was transfected into CHO cells
by electopermeabilization. Cell supernatants were recovered
to assay the production level and the enzymatic activity of
secreted molecules. Each batch solution was characterized
by its activity (U/mL), protein concentration (mg/mL), and
specific activity. Peroxidative activity was determined using
𝑜-dianiside as the substrate. Protein concentration was mea-
sured using the Lowry assay, with ovalbumin as a standard.
Each batch was checked for endotoxin using the Lonza
Endotoxin Detection Kit QCL-1000 (Catalog Number: 50-
647U). Concentrationwas always less than 100 pg/mL,which,
taking into account the final dilution of theMPO-treated LDL
fraction, would contribute a final concentration of less than
0.1 pg/mL to the Mox-LDL supplemented medium added to
the cells.
2.17. Isolation of Native LDL and Mox-LDL Preparation.
Lipoprotein particles were isolated from plasma from sterile
blood pouches using density-gradient ultracentrifugation.
The native LDL fraction (𝑑 = 1.019–1.063) was stored under
nitrogen at 4∘C in the dark and oxidized according to the
procedure described below: prior to oxidation, native LDL
were gel filtered (PD-10 column, Pharmacia) and 1.6mg
of native LDL was oxidized by 2.1 chlorinating units of
recombinantMPO, to generate the oxidized LDL (Mox-LDL)




in 2mL PBS at pH 6.5 for
5 minutes. LDLs were desalted again after MPO treatment.
Protein concentration was measured by the Lowry assay,
using ovalbumin as a standard.
2.18. Statistical Analysis. GraphPad Prism was used for the
analysis. Data were evaluated either by one-way ANOVA or
Student’s 𝑡-tests. 𝑃 values of <0.05 (∗), <0.01 (∗∗), and <0.001
(∗ ∗ ∗) were considered significant.
3. Results
3.1. MPO-Oxidized LDL (Mox-LDL) Interferes with Cell
Behavior in HUVECs. In order to monitor in real-time the
influence of Mox-LDL on the dynamics of cell adhesion and
proliferation in HUVECs, the xCELLigence system [18] was
exploited. Cells were seeded and the impedance of the EC
layer was measured in real time. The impedance Cell Index
(CI) progressively increased over 24 hours after seeding, due
to intrinsic cell properties probably including a combination
of cell adherence, morphological changes, and proliferation.
After 24 hours of signal acquisition, cells reached confluence
and covered up the whole surface area of the E plate wells and
impedance reached a plateau. Native LDL or Mox-LDL was
then added to the wells and the impedance measurements
were carried on for another 24 hours. While the impedance
CI remained stable in the mock-treated and native LDL-
treated wells, it significantly decreased in the Mox-LDL
treated wells (Figure 1). As the impedance CI is affected
by cell adhesion, proliferation, attachment, spreading, and


















Figure 1: Dynamic real-timemonitoring of HUVEC behavior using
the xCELLigence RTCA system. Impedance Cell indexes (CIs) of
HUVECs were monitored during 48 hours. Cells were seeded and
incubated for 25 hours after which the medium was supplemented
with native LDL, Mox-LDL, or mock medium. The result shown
is representative of three independent experiments performed in
duplicate.
with one of these cell parameters. We therefore decided to
further address these EC properties in dedicated assays.
3.2. Mox-LDL Decreases Tubulogenesis in HUVECs. In order
to investigate the effect of Mox-LDL on the ability of ECs
to build a vascular network, an in vitro tubulogenesis assay
was performed using HUVECs. ECs were initially incubated
in control medium or medium supplemented with native
LDL or Mox-LDL. After 24 h, cells were switched to Matrigel
coated plates overnight. As expected, control ECs formed a
characteristic capillary-like network [22]. However as illus-
trated in Figure 2(a), Mox-LDL partially inhibited the ability
of EC to build a vascular network, whereas control native
LDL had no effect. Quantification analysis indicated that
the decrease of the cumulative vessel length in presence of
Mox-LDL was higher than 50% (Figure 2(b)), demonstrating
that Mox-LDL severely affected angiogenic activities of ECs.
Monitoring network formation in real time during 9 hours
indicated that this effect was related to an inhibition of sprout
projection rather than to regression of preformed network
(data not shown).
3.3. Mox-LDL Inhibits Migratory Abilities of ECs In Vitro.
Because tubulogenesis is highly dependent on cell migra-
tion, we next investigated the action of Mox-LDL in an
in vitro wound healing assay [23]. In this assay, cultured
HUVEC monolayers preincubated for 24 hours in mock
medium, native LDL, or Mox-LDL supplemented medium
were allowed to recolonize a scratched area for 8 hours. As
illustrated by Figure 3(a), the migration ability of Mox-LDL-
treated ECs was decreased, an effect not seen in presence of
native LDL. Cell migration was assessed by measuring the
distance between the scratch edges of the cell free area at
𝑡 = 8 h and expressing it as a percentage of the initial scratch
width at 𝑡 = 0 h. As shown in Figure 3(b), while 57% and 46%
of the scratch girth remained unclosed after 8 hours in mock


















Figure 2:The effect ofMox-LDL treatment onHUVEC tubulogenesis. (a) Representative fields ofHUVEC cultures in tubulogenic conditions.
HUVECs were seeded on Matrigel supplemented with mock medium (CTL), native LDL (LDL), or Mox-LDL (MoxLDL) and incubated
overnight. The fields are representative of three independent experiments performed in duplicate. (b) Quantification of tubulogenesis in
HUVEC cultures. After overnight incubation in Matrigel supplemented with mock medium (CTL), native LDL (LDL), or Mox-LDL (Mox-
LDL), pictures were taken of 4.906mm square fields. Total tubule network length was then measured using the Image J computer program.
Shown data are expressed as total tubule network length for each condition and normalized to the untreated control set as 100%.Mean ± SEM
on 3 independent experiments performed in duplicate. ∗∗∗𝑃 < 0.001 versus control (ANOVA, Turkey’s multiple comparison test).
and LDL treated cells, respectively, 80% remained unclosed
in Mox-LDL treated cells.
3.4. Mox-LDL Inhibits ECs Directional Chemomigration. We
then evaluated the effect of Mox-LDL on HUVEC chemomi-
gration in a modified Boyden chamber assay [24]. HUVECs
were initially cultured in the presence or absence of native
LDL orMox-LDL for 24 hours. Cells were then harvested and
seeded in the bottom of the upper chamber of the Boyden
chamber in similar conditions. Directional cell migration
was induced towards a VEGF gradient. As illustrated by
Figure 4(a), EC migration was diminished in presence of
Mox-LDL. In contrast, native LDL had no effect. Quantifi-
cation analysis indicated that Mox-LDL treatment decreased
cell migration by more than 60% (Figure 4(b)). Altogether,
these results indicate that both random and directional
migratory abilities of ECs were severely affected byMox-LDL
addition.
3.5. Mox-LDL Does Not Interfere with HUVEC Proliferation
or Viability. Next, we checked whether the negative effect of
Mox-LDL on HUVEC tubulogenesis and migration was due
to a negative effect on cell proliferation or viability. To this
aim, we incubated EC in culture medium supplemented with
native LDL orMox-LDL or controlmedium for 24 hours. ECs
were harvested and submitted to FACS analyses, first using
a combination of Ki67 antibodies and LIVE/DEAD stain to
evaluate cell death and proliferation [25]. The proportion of
apoptotic cells was also assessed by annexin V and propidium
Iodide staining [26]. No significant disparities regarding
cell proliferation, viability, or death (apoptosis or necrosis)
between any of the conditions (Figures 5(a) and 5(c)) could
be detected. Statistical analyses of results coming from
independent experiments confirmed that the percentage of
proliferating, dead or PS positive cells, remained comparable
in all conditions (Figures 5(b) and 5(d)).
3.6. Mox-LDL Has No Effect on Adhesion Foci. Our data
pointed at an effect of Mox-LDL on HUVEC motility. Key
players in this phenomenon are the structures mediating
cells/ECM interaction called adhesion plaques or adhesion
foci. We therefore analyzed the effect of our treatments on
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Figure 3: The effect of Mox-LDL treatment on wound closure after HUVEC monolayer scratch. (a) Scratched monolayers of HUVEC cells.
HUVECwere seeded, allowed to reach confluence, and incubated for 24 hoursmore. HUVECswere then either treated or not with native LDL
orMox-LDL for 24 h.Wounds were then made by scratching the confluent cell monolayers with a yellow pipet tip and washed twice and cells
were incubated for additional 8 hours in the same conditions. Pictures were taken at time of wounding and eight hours later in all conditions.
Black lines defining wound edges were superimposed to the pictures. The results shown are representative of three independent experiments
performed in duplicate. (b) Quantification of (a). After scratching the HUVEC monolayers to induce wounds, cells were incubated for
additional 8 hours in the above conditions, pictures were taken, and the distance between the wound edges were measured in all conditions.
The distance that remained cell-free at 𝑡 = 8 h was calculated as a percentage of the initial wound width at time of scratching 𝑡 = 0 h. Mean ±
SEM on 3 independent experiments performed in duplicate. ∗𝑃 < 0.05 versus control (ANOVA, Turkey’s multiple comparison test).
these adhesion complexes. IF staining of paxillin, a classical
marker of adhesion foci, did not show any effect of Mox-
LDL on the occurrence, size, or subcellular distribution of
adhesion complexes in ECs as shown in Supplementary
Figure I (see Supplementary Material available online at
http://dx.doi.org/10.1155/2014/134635). Focal adhesion kinase
(FAK) is a major player in signal transduction pathways
responsible for matrix reorganization, cell-matrix adhesion,
and cell migration [27]. Therefore, we investigated phos-
phorylation of FAK upon Mox-LDL treatment. Western
blot analyses of HUVECs using an anti-phospho-FAK (Tyr
576) antibody did not reveal any effect of Mox-LDL on
phosphorylated FAK levels (Supplementary Figure II) or
localization (data not shown), thus confirming thatMox-LDL
has no impact on EC adhesive properties.
3.7. Angiogenesis-Related Gene Expression Profiling in Mox-
LDL Treated HUVECs. As tubulogenesis is widely accepted
as an in vitro model of early steps of in vivo angiogenesis,
the human angiogenesis StellARray technique was used to
study the expression of 94 preselected genes involved in
angiogenesis pathways. Treatment of HUVECs with Mox-
LDL significantly altered the expression of four of the tested
genes, including HO-1 (Supplementary Table I).
















Figure 4: The effect of Mox-LDL treatment on HUVEC cell migration. (a) HUVEC cells which migrated through membranes. HUVEC
cells were incubated for 24 hours in culture medium supplemented with mock medium, native LDL, or Mox-LDL and then seeded onto the
membrane in the upper chamber of a modified Boyden chamber in conditions inducing the migration to the lower chamber. After 8 hours
cells that migrated to the lowermembrane side were fixed and stained.The results shown are representative of three independent experiments
performed in duplicate. (b) Quantification of (a). Pictures were taken of fixed and stained cells that migrated through the membrane. Cells
were counted and numbers of migrated cells were expressed as fold over control untreated cells. Mean ± SEM on 3 independent experiments
performed in duplicate. ∗∗∗𝑃 < 0.001 versus control (ANOVA, Turkey’s multiple comparison test).
3.8. Transcriptional Effects of Mox-LDL Treatment in
HUVECs. In order to explore the molecular mechanisms
underlying Mox-LDL effects and HO-1 induction, we sought
to check whether a change in microRNAs (miRs) expression
patterns could be correlated with the phenotypic Mox-LDL
actions in HUVECs [28]. Hence, RNA was extracted from
HUVECs incubated in control or LDL and Mox-LDL
supplemented medium. It was first analyzed by the TaqMan
Low Density Array (TLDA) technique. Several miRs were
identified to be differentially expressed exclusively in Mox-
LDL treated HUVECs (see Supplementary Table II). TLDA
results were validated by qRT-PCR conducted on each of the
differentially expressed miRs using specific primers. This led
to a high-confidence miR signature of miR-133a, miR-203,
miR-22 overexpression (4, 2.5, and 8.5 times; resp.), and
miR-672 down-regulation (3 fold) uponMox-LDL treatment
(see Supplementary Table III). In particular, miR-22 was
upregulated 8.5 times in Mox-LDL treated cells as compared
to control.
3.9. A Functional Relation between miR-22 Induction, HO-
1 Expression, and Tubulogenesis Inhibition by Mox-LDL in
HUVECs. As we established an effect of Mox-LDL on
HUVEC motility and tubulogenesis, as well as a correlated
mRNA and micoRNA signature, we assessed a causal and
functional interaction between these three observations; we
first screened the upregulated mRNA 3󸀠UTR for putative
consensus sites targeted by up- or downregulated miRs. In
silico analysis uncovered a miR-22 target site located between
positions 276 and 299 in the HO-1 3󸀠UTR. In order to
test a causal effect of miR-22 on HO-1 gene expression, we
examined the effect of miR-22 knockdown on the expression
of HO-1. As illustrated in Figure 6(a), depletion of miR-22
prevented HO-1 expression even when the cells were treated
with Mox-LDL.
In order to test a causal effect of miR-22 on tubulogenesis,
we prevented miR-22 expression in Mox-LDL treated ECs
and assessed their tubulogenic activities in a Matrigel assay.
As illustrated in Figure 6(b), inhibition of miR-22 specifically
counteracted Mox-LDL negative effect on tubulogenesis. We
next asked if the functionally connected miR-22 and HO-1
upregulations under Mox-LDL treatment could account for
the negative phenotypical effect of Mox-LDL on tubulogene-
sis.We also verified that overexpression ofHO-1 recapitulated
the inhibitory effect of Mox-LDL treatment on angiogenic
properties of HUVECs (Supplementary Figure IV).







































































































































































































Figure 5: Effect of Mox-LDL treatment on HUVEC proliferation. (a) A representative Flow cytometry analysis of HUVEC cells incubated
for 24 hours in culture medium supplemented with mock medium, native LDL, or Mox-LDL. Cells were then harvested and analyzed for
the dead cell stain and the Ki67 proliferation marker. Percentages of cells located in the different quadrants are indicated. (b) Statistical
analysis of the percentages of proliferating cells determined as in (a) on 3 independent experiments performed in duplicate. Mean ± SEM
(ANOVA, Turkey’s multiple comparison test). Effect of Mox-LDL treatment on HUVEC cell death. (c) A representative flow cytometry
analysis of HUVEC cells incubated for 24 hours in culture medium supplemented with mock medium, native LDL, or Mox-LDL. Cells were
then harvested and analyzed for PI DNA staining and phosphatidylserine annexin V staining. Percentages of cell located in the different
quadrants are indicated.The results are representative of three independent experiments performed in duplicate. (d) Statistical analysis of the
percentages of PI-negative annexinV positive cells determined as in (c) on 3 independent experiments performed in duplicate. Mean ± SEM
(ANOVA, Turkey’s multiple comparison test).
4. Discussion
Our data indicate that Mox-LDL interferes negatively with
HUVECmobility (motility, migration, and tubulogenesis) in
vitro through an increase of miR-22 and HO-1 expression.
Our study must be discussed in light of previously
published studies on the effects of ox-LDL on (i) cell
death/apoptosis and (ii) “angiogenesis.”
Regarding cell death, in contrast to previous reports
showing that ox-LDL is able to induce apoptosis and reduce
the viability of vascular ECs [29, 30], we found no effect of
Mox-LDL on cell proliferation and death. This discrepancy
could be related to the experimental design, cell type, and
oxidation protocol or ox-LDL concentration. We used an
oxidizing agent and ox-LDL concentrations that are both
pathophysiological which,we believe, aremore closely related
to an in vivo situation. In particular, copper widely used to
oxidize LDL in vitro is unlikely to be available at concentra-
tions sufficient to generate observed ox-LDL concentrations.
Previously proposed actors such as lipoxygenase or NADPH
oxidase have now been discarded. Although new actors
could be proposed such as VPO (peroxidasin), MPO is
a favourite in vivo actor: it oxidizes LDL in vitro; high
serum level is a risk factor in CVD; MPO oxidized LDL is
detected in vivo. We used oxidized LDL concentrations that
have been previously detected in vivo. Finally, we applied
10 Mediators of Inflammation






























































Figure 6: (a) Differential HO-1 expression between HUVECs submitted to different treatments: CTL (control mock-treated cells), miR-
22 K.D (cells treated with miR-22 inhibitor), miR-22 K.D; Mox-LDL (cells treated with miR-22 inhibitor and Mox-LDL), miR Neg Ctl;
Mox-LDL (cells treated with control miR and Mox-LDL), and Mox-LDL (cells treated with Mox-LDL). HUVECs were either treated or
not with miR-22 inhibitor or miR inhibitor negative control. HUVEC were incubated for 24 hours in culture medium supplemented with
mock medium (CTL) or Mox-LDL. Total RNA was extracted and analyzed by qRT-PCR using HO-1-specific primers. Pooled data from
3 independent experiments are shown. ∗∗∗𝑃 < 0.001 (Student’s 𝑡 test). (b) The effect of miR-22 knockdown on Mox-LDL treatment in
HUVEC tubulogenesis. Representative fields of HUVEC cultures in tubulogenic conditions. HUVECs were either treated or not with miR-22
inhibitor or miR inhibitor negative control. Afterwards, cells were cultured in the presence or absence of Mox-LDL for 24 hours. HUVECs
were then seeded onMatrigel supplemented withmockmedium (CTL) orMox-LDL (Mox-LDL) and incubated overnight. (c) Quantification
of tubulogenesis in HUVEC cultures. After overnight incubation in Matrigel supplemented with mock medium (CTL) or Mox-LDL (Mox-
LDL), pictures were taken of 4.906mm square fields. Total tubule network length was then measured using the Image J computer program.
Shown data are expressed as total tubule network length for each condition and normalized to the “miR-22 inhibitor; nontreated” control
condition set as 100%.Mean ± SEMon 3 independent experiments performed in duplicate. ∗∗∗𝑃 < 0.001 versusMox-LDL (ANOVA, Turkey’s
multiple comparison test).
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a quality control procedure assessing the in-vivo-like LDL
oxidation levels. These conditions could elicit specific signal
transduction pathways as recently illustrated by their unique
ability to trigger a pathway involving PLA2 in macrophages
[31].
Regarding angiogenesis, we have shown for the first
time that pathophysiological concentrations of Mox-LDL
induce significant functional changes in human ECs. Thus in
our hands, ox-LDL inhibits HUVEC in vitro tubulogenesis,
motility, and migration, properties associated with in vivo
angiogenesis. This has to be confronted with the few reports
regarding an ox-LDL effect on angiogenesis. These data are
once again contradictory, a fact which could be again related
to different experimental protocols and in particular different
ox-LDL concentrations. Thus, while earlier studies showed
an inhibitory effect of ox-LDL and hypercholesterolemia
on angiogenesis-like endothelial growth [29], some recent
studies report that ox-LDL may play a proangiogenic role at
low concentrations [32, 33]. Our observations might relate
to the fact that we used oxidizing agent and concentrations
which are both pathophysiological to be as close as possible
to in vivo situations.
After our phenotypical analysis, we aimed at determining
the molecular mechanisms interfering with EC motility.
Although the simplest hypothesis would ultimately involve an
interference with adhesion foci function we could not detect
any effect of Mox-LDL on EC adhesives properties.
We next analyzed changes in gene expression associ-
ated with Mox-LDL treatment. Our results suggest that
the observed phenotypic effect could be explained at the
molecular level by HO-1 gene expression regulation by miR-
22. The HO-1 enzyme is induced in response to stress stimuli
such as oxidative stress and catalyzes the degradation of heme
into carbon monoxide, biliverdin, and free iron. There are
numerous studies linking HO-1 to angiogenesis pathways
[34–38] suggesting both positive and negative effects. Other
studies also report the antiangiogenic activity of miR-22
[39–41]. Two studies in particular, one performed in a
colon cancer model [42] and the other in a hepatocellular
carcinoma model [43], linked respectively miR-22 and HO-1
upregulation to a decrease in cellmigration, invasiveness, and
wound healing, although independent of Mox-LDL treat-
ment, but nevertheless in accordance with our observations
performed with Mox-LDL treatment. Finally, several reports
suggest howHO-1 could interferewith angiogenesis. It indeed
induces the expression of pro- (CCL-2, CXCL-8) or anti-
(CXCL-10) angiogenic chemokines. In this later case HO-1
overexpression induced secretion by EC of CXCL-10 which
was able to inhibit EC growth [44]. We did not see any
effect on CXCL10 expression nor on cell growth. To conclude
about the role of HO-1, it is worth mentioning that none of
the previous publications, although some claim that HO-1
enzymatic activity is required, investigated heme availability
or CO, iron, and bilirubin production.
In order to check the causative role of the miR-22/HO-1
axis in the Mox-LDL signal transduction pathway, we inhib-
ited miR-22 expression in ECs. MiR-22 inhibition abrogated
Mox-LDL negative effect on tubulogenesis. Furthermore,
miR-22 knockdown prevented HO-1 overexpression and
induction by Mox-LDL. We also checked the effect of HO-1
knockdown or ectopic expression on EC angiogenic abilities.
While HO-1 knockdown indicated that a minimal amount
of HO-1 is mandatory for in vitro angiogenesis, its overex-
pression was deleterious. This supports previous indications
of a complex role of HO-1, whose lower concentrations had
stronger effects than higher concentrations [44] and indicates
that appropriate levels of HO-1 are crucial for tubulogenesis.
Our data fill gaps in the Mox-LDL signal transduction
pathway. Ox-LDL have been previously reported to bind to
the LOX-1 scavenger receptor and to trigger signal trans-
duction pathways involving several kinases including JNK,
pKC, ERK 1 and 2, Raf, and IP3K [34, 45]. We focused
on the end of this pathway: control of gene expression and
phenotypic effects. Bioinformatics prediction tools pointed at
a putative miR-22 target site in HO-1 mRNA and suggested
a direct regulation of the latter by the first. However only
rare cases of direct miR positive effects have been reported
previously [46, 47]. Reporter gene assays conducted in order
to assess this possibility gave indeed negative results (data not
shown). Putative miR-22 target sites, detected in the HO-1
promoter, suggested a possible miR transcriptional effect as
previously documented [48, 49]. Reporter gene assays did not
support that suggestion either. Reports of miR positive effects
through inhibition of a negative regulator are more frequent.
In our case, this miR target remains to be identified. Yet, an
alternative HO-1 control by miR-22 could happen through
inhibition of nonsense-mediated RNA decay (NMD). For
example, the brain-specific miR-128 was recently shown to
induce a battery of transcripts in neuronal cells through
NMD repression by targeting the exon junction complex core
component MLN51 and the RNA helicase UPF1 [50].
We first rejected the 3 other miRs whose expression was
affected byMox-LDL due to the lack of target sites in theHO-
1 3󸀠UTR. In the light of our negative reporter assays, they
nevertheless deserve to be considered again, as they could
act indirectly (for example, by interfering with the expression
of a microRNA or a protein itself acting directly on HO-1
expression). This will be addressed in our future work.
The simplest model which best explains our observation
is as follows. LDL modified by MPO binds to the scavenger
receptor LOX-1 on ECs. This triggers an oxidative stress
signaling pathway that will stimulate the binding of NRF-like
transcription factor to potential consensus sequence in miR-
22 promoter [51]. This in turn increases miR-22 expression.
Mir-22 indirectly increasesHO-1 expression through uniden-
tified targets possibly by repressing NMDmechanisms in the
cell. This interferes with cell motility.
However uncertainties remain in this transduction path-
way. First, the nature of the molecular actor linking miR-22
and HO-l is unknown. The cell specificity of this link should
be addressed aswe could not perform the reporter gene assays
in HUVECs. Secondly, the involvement of HO-1 enzymatic
activity and the nature of its target is still hypothetic.
Our data have all been obtained in vitro. They suggest
that Mox-LDL interferes with angiogenesis in vivo. Thus,
high LDL concentrations in patients’ serum would impair
angiogenesis and hinder EC ability to cope with a dam-
aged endothelium. These mechanisms are at play in several
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pathological or physiological conditions. For example, high
LDL levels would impair angiogenesis-dependent tumour
growth, although this seems in contradiction to reports of
obesity as a risk factor for some cancers. More appropriately,
while it is well known that high LDL concentrations are a risk
factor for cardiovascular diseases through atherosclerosis,
our data suggest that they would furthermore contribute to
the bad evolution of the disease through interfering with
“reendothelialization” of vascular denudations, atheroma-
associated wounds, stents, aneurysms, infarcts, or places of
restenosis. More generally high ox-LDL levels could also
negatively impact the progression of all the pathologies
associated with endothelial desquamation, such as vasculitis,
lupus erythematosus, sickle cell anemia, thalassemia, septic
shock, infections (rickettsiae, CMV), or cancer.
5. Conclusion
Atherosclerosis chiefly contributes to cardiovascular disease,
the first cause of death worldwide, which includes cerebral
vascular accidents and myocardial infarctions. Atheroscle-
rosis is linked to the accumulation of oxidized LDL in the
vascular wall, affecting its function.We show that pathophys-
iological concentrations of oxidized LDL impair the mobility
and the angiogenic capability of endothelial cells. We identify
a microRNA (a small RNA able to tune gene expression),
miR-22, and the gene coding for heme oxygenase 1 whose
overexpression is instrumental in this phenotypical effect.
Our results suggest that lipid rich diets that enhance the LDL
and ox-LDL levels not only cause atheroma plaque formation
but also interfere with the endothelial wound healing process;
they can therefore contribute to the progression of the
disease; they can influence negatively all clinical conditions
associated with endothelial desquamation.They can interfere
with denudations resulting from medical protocols such as
catheterization or stenting.
Nonstandard Abbreviations and Acronyms
LDL: Low density lipoprotein
MPO: Myeloperoxidase
ox-LDL: Oxidized low density lipoprotein
Mox-LDL: Myeloperoxidase oxidized low density
lipoprotein
HO-1: Heme oxygenase 1
EC: Endothelial cell.
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